BIP
IDXG

Brandes Investment Partners’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History

Brandes Investment Partners’s Portfolio IDXG Stock Details IDXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-9,100
Closed -$93K – 161
2017
Q4 		$93K Buy
+9,100
New +$110K ﹤0.01% 143
2013
Q3 		– Sell
-108
Closed -$51K – 185
2013
Q2 		$51K Buy
+108
New +$49K ﹤0.01% 163

Other funds holding IDXG

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
LCC
Lincoln Capital Corp East Greenwich, Rhode Island $308M AUM 24.88% 1-Year Est. Return

Brandes Investment Partners's IDXG Position: Q1 2018 in Review

Brandes Investment Partners sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q1 2018, closing a stake of 9,100 shares — an estimated $93K sold.

Brandes Investment Partners first reported a position in IDXG in Q2 2013 and held it in 2 quarters. The position peaked at $93K in Q4 2017. 14 funds tracked by Wall St. Rank hold IDXG as of Q1 2018.

  • Brandes Investment Partners reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Brandes Investment Partners sold 9,100 Interpace Biosciences, Inc. Common Stock shares in Q1 2018, an estimated $93K.
  • Brandes Investment Partners first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2013 and held it in 2 quarters.
  • Brandes Investment Partners's Interpace Biosciences, Inc. Common Stock position peaked at $93K in Q4 2017.
  • 14 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q1 2018.

Based on Brandes Investment Partners's 13F filing for Q1 2018, filed 15 May 2018.